Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025
Consolidated Financial Results for the Three months Ended March 31, 2025 (IFRS)
Nxera Pharma, Jan-Mar (1Q) Net Income Loss Narrows
Nxera’s Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as Potential Treatment for Adults with Schizophrenia
Notice of Issuance of New Shares Under RSU Plan and Determination of Pmt Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU
Nxera Pharma’s Partner Tempero Bio Initiates Phase 2 Trial with TMP-301 for Alcohol Use Disorder
Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris
Correction to “Notice Regarding Reduction of the Amount of Capital Reserve and Disposition of Surplus”
Notice Regarding Reduction of the Amount of Capital Reserve and Disposition of Surplus
Nxera Pharma Proposes Changes to its Board of Directors
Notice Regarding Partial Amendment to the Articles of Incorporation
Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2024
Consolidated Financial Results for the FY2024 (IFRS)
Nxera Pharma, Last Fiscal Year's Net Income Loss Narrows, Current period performance is undisclosed.
Nxera Pharma Enrols First Insomnia Patient in its Phase 3 Clinical Trial of Daridorexant in South Korea
Nxera Pharma’s Partner Centessa Initiates Phase 2 Trial with ORX750, a Novel Orexin Receptor 2 (OX2R) Agonist
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2024
Consolidated Financial Results for the Nine months Ended September 30, 2024 (IFRS)
Nxera Pharma Co., Ltd., January-September (Third Quarter Cumulative) Net Income Loss Narrows, July-September Net Income Turns to Profit
Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ in Japan